Tobramycin: Clinical Trials

12 trials of Tobramycin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 2 unknown, 1 recruiting, 1 terminated. 12 Phase 2, 5 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 212Completed 8, Unknown 2, Recruiting 1, Terminated 1
Phase 15Completed 3, Unknown 2

Follow Tobramycin: new trials by email Literature Review of Tobramycin trials Research Report on Tobramycin

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Antibiotic Impregnated Bone Graft to Reduce Infection in Hip Replacement.
Vancomycin + Tobramycin, Saline - Arthroplasty, Replacement, Hip, Osteoarthritis, Hip
Phase 2RecruitingUniversity Hospital, Linkoeping11002022-04-012026-07-10
Abbreviated Protocol for Two-Stage Exchange
VT-X7 Treatment System with Tobramycin Sulfate, Standard of Care, Two-stage exchange arthroplasty - Prosthetic Joint Infection
Phase 2CompletedOsteal Therapeutics, Inc.762021-11-012026-10-15
DPI-Tobra-Kind Cyclops® in Children With Cystic Fibrosis
Tobramycin - Cystic Fibrosis
Phase 1 / Phase 2UnknownUniversity Medical Center Groningen102019-05-292021-10-01
Safety and Efficacy in Patients Treated for Hip or Knee PJI With Vancomycin and Tobramycin Joint Irrigation
vancomycin hydrochloride and tobramycin sulfate - Prosthetic Joint Infection
Phase 2CompletedOsteal Therapeutics, Inc.152018-10-262022-01-11
Topical Antibiotics in Chronic Rhinosinusitis
Mupirocin, Tobramycin, Levofloxacin - Chronic Rhinosinusitis (Diagnosis)
Phase 1 / Phase 2CompletedMayo Clinic192018-09-262022-04-20
Once Daily Aminoglycoside Pharmacokinetics and Optimal Dosing in the Burn Population: A Prospective Study
Tobramycin - Burns, Infection
Phase 1 / Phase 2CompletedSandra Walker102015-03-012015-12-14
Pharmacokinetic Evaluation and Tolerability of Dry Powder Tobramycin by a Novel Device in Patients With Non Cystic Fibrosis Bronchiectasis
Tobramycin - Bronchiectasis
Phase 1 / Phase 2CompletedUniversity Medical Center Groningen82013-10-012014-12-16
Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus® /Pulmoaid® in Patients With Cystic Fibrosis
Tobramycin - Cystic Fibrosis
Phase 1 / Phase 2UnknownErempharma362011-04-012011-04-18
Clinical Trials to Reduce the Risk of Antimicrobial Resistance
IV meropenem, I.V. Meropenem, Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h - Bacterial Pneumonia
Phase 2TerminatedUniversity of Florida432010-09-012017-09-29
Nasal Inhalation of Tobramycin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization
Tobramycin (Gernebcin®) - Cystic Fibrosis, Pseudomonas Aeruginosa
Phase 2CompletedUniversity of Jena92008-10-012014-12-04
Comparison of Two Treatment Regimens to Reduce PA Infection in Children With Cystic Fibrosis
Tobramycin solution for inhalation (TOBI), Oral placebo, Oral ciprofloxacin - Cystic Fibrosis, Pulmonary Disease, Chronic Obstructive
Phase 2CompletedSeattle Children's Hospital3042004-09-012014-02-28
A Study of the Safety and Efficacy of Tobramycin for Inhalation in Young Children With Cystic Fibrosis
Tobramycin for Inhalation - Cystic Fibrosis
Phase 2CompletedNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)982000-02-012010-03-02

Conditions studied

Cystic Fibrosis (5)  ·  Pseudomonas Infections (2)  ·  Bronchiectasis (1)  ·  Burns (1)  ·  Disease (1)  ·  Infections (1)  ·  Lung Diseases (1)  ·  Osteoarthritis, Hip (1)  ·  Pneumonia, Bacterial (1)  ·  Pulmonary Disease, Chronic Obstructive (1)

Sponsors

Osteal Therapeutics, Inc. (2)  ·  University Medical Center Groningen (2)  ·  Erempharma (1)  ·  Mayo Clinic (1)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1)  ·  Sandra Walker (1)  ·  Seattle Children's Hospital (1)  ·  University Hospital, Linkoeping (1)  ·  University of Florida (1)  ·  University of Jena (1)

Countries

United States (6)  ·  France (2)  ·  Germany (2)  ·  Netherlands (2)  ·  Canada (1)  ·  Spain (1)  ·  Sweden (1)

Top investigators

Bryan Springer, MD (2)  ·  Bonnie W. Ramsey (1)  ·  David Waltz, M.D. (1)  ·  Gabriel Bellon (1)  ·  Garret W Choby, MD (1)  ·  George L Drusano, MD (1)  ·  George Retsch-Bogart, M.D. (1)  ·  George Retsch-Bogart, MD (1)  ·  Gerard Koppelman, Prof. (1)  ·  Huib Kerstjens, MD, PhD (1)  ·  Isabelle Durieu, Pr (1)  ·  Jeffrey Wagener, M.D. (1)  ·  Jochen Mainz, M.D. (1)  ·  Michael Konstan, M.D. (1)

Results publications

PMID 21893650, PMID 24596456, PMID 25972024, PMID 26288390, PMID 29038277, PMID 38604274, PMID 42731828

NIH funding

M01RR000037 (1), R01DK057755 (1), U01HL080310 (1)